PMID- 36905514
OWN - NLM
STAT- MEDLINE
DCOM- 20230314
LR  - 20230424
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 2618
DP  - 2023
TI  - In Vitro Generation of Human Cross-Presenting Type 1 Conventional Dendritic Cells 
      (cDC1s) and Plasmacytoid Dendritic Cells (pDCs).
PG  - 133-145
LID - 10.1007/978-1-0716-2938-3_10 [doi]
AB  - Dendritic cells (DCs) represent one of the most important immune cell subsets in 
      preventing the host from pathogen invasion by promoting both innate and adaptive 
      immunity. Most research on human dendritic cells has focused on the 
      easy-to-obtain dendritic cells derived in vitro from monocytes (MoDCs). However, 
      many questions remain unanswered regarding the role of different dendritic cell 
      types. The investigation of their roles in human immunity is hampered by their 
      rarity and fragility, which especially holds true for type 1 conventional 
      dendritic cells (cDC1s) and for plasmacytoid dendritic cells (pDCs). In vitro 
      differentiation from hematopoietic progenitors emerged as a common way to produce 
      different DC types, but the efficiency and reproducibility of these protocols 
      needed to be improved and the extent to which the DCs generated in vitro 
      resembled their in vivo counterparts required a more rigorous and global 
      assessment. Here, we describe a cost-effective and robust in vitro 
      differentiation system for the production of cDC1s and pDCs equivalent to their 
      blood counterparts, from cord blood CD34(+) hematopoietic stem cells (HSCs) 
      cultured on a stromal feeder layer with a combination of cytokines and growth 
      factors.
CI  - (c) 2023. The Author(s), under exclusive license to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Luo, Xinlong
AU  - Luo X
AD  - Aix Marseille Univ, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, 
      Turing Center for Living Systems, Marseille, France.
FAU - Balan, Sreekumar
AU  - Balan S
AD  - Aix Marseille Univ, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, 
      Turing Center for Living Systems, Marseille, France.
AD  - The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York 
      City, NY, USA.
FAU - Arnold-Schrauf, Catharina
AU  - Arnold-Schrauf C
AD  - Aix Marseille Univ, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, 
      Turing Center for Living Systems, Marseille, France.
AD  - Celgene Austria GmbH, Vienna, Austria.
FAU - Dalod, Marc
AU  - Dalod M
AD  - Aix Marseille Univ, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, 
      Turing Center for Living Systems, Marseille, France. dalod@ciml.univ-mrs.fr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (Antigens, CD34)
SB  - IM
MH  - Humans
MH  - Reproducibility of Results
MH  - *Hematopoietic Stem Cells
MH  - Cell Differentiation
MH  - Antigens, CD34/metabolism
MH  - *Dendritic Cells
OTO - NOTNLM
OT  - CD34+ hematopoietic stem cells
OT  - Hematopoiesis
OT  - Notch
OT  - Plasmacytoid dendritic cells
OT  - Stromal cells
OT  - Type 1 conventional dendritic cells
EDAT- 2023/03/12 06:00
MHDA- 2023/03/15 06:00
CRDT- 2023/03/11 11:17
PHST- 2023/03/11 11:17 [entrez]
PHST- 2023/03/12 06:00 [pubmed]
PHST- 2023/03/15 06:00 [medline]
AID - 10.1007/978-1-0716-2938-3_10 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2023;2618:133-145. doi: 10.1007/978-1-0716-2938-3_10.